Both DFT1 and DFT2 are markedly sensitive to CHEK1/CHEK2 inhibitor AZD7762, and poly-ADP ribose polymerase (PARP) inhibitors Talazoparib and Olaparib, suggesting that DFT cancers are intolerant of DNA damage (Figure 5D; Table S7), perhaps explaining the remarkable genomic stability observed in DFT1 (Deakin et al., 2012, Murchison et al., 2012). This evidence concerns the gene CHEK2 and cancer.